tradingkey.logo

tradingkey.logo
怜玢


Chemomab Therapeutics Ltd

CMMB
りォッチリストに远加
1.410USD
+0.050+3.68%
終倀 07-27 16:00ET15分遅れの株䟡
40.61M時䟡総額
8.09盎近12ヶ月PER

詳现情報 Chemomab Therapeutics Ltd 䌁業名

Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Chemomab Therapeutics Ltdの䌁業情報


䌁業コヌドCMMB
䌚瀟名Chemomab Therapeutics Ltd
䞊堎日Aug 14, 2012
最高経営責任者「CEO」Mor (Adi)
埓業員数16
蚌刞皮類Depository Receipt
決算期末Aug 14
本瀟所圚地Kiryat Atidim, Building 7
郜垂TEL AVIV-YAFO
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜Israel
郵䟿番号6158002
電話番号972773310156
りェブサむトhttps://www.chemomab.com/
䌁業コヌドCMMB
䞊堎日Aug 14, 2012
最高経営責任者「CEO」Mor (Adi)

Chemomab Therapeutics Ltdの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
14.48K
+95.59%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Dr. David M. Weiner, M.D.
Dr. David M. Weiner, M.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Mr. Jack Lawler
Mr. Jack Lawler
Chief Development Officer
Chief Development Officer
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
14.48K
+95.59%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--

よくある質問

Chemomab Therapeutics Ltdの䞊䜍5名の株䞻は誰ですか


Chemomab Therapeutics Ltdの䞊䜍5名の株䞻は以䞋のずおりです。Ms. Sigal Fattal, CPA

Chemomab Therapeutics LtdCMMBの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Chemomab Therapeutics Ltdの株匏を保有しおいる機関は33瀟あり、保有株匏の総垂堎䟡倀は玄402.96Kで、党䜓の5.60%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-450971.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。